XML 81 R51.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaboration and License Agreements - Additional Information (Detail) (USD $)
 12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2011
Dec. 31, 2012
Feb. 28, 2014
Subsequent Event [Member]
Dec. 31, 2013
Servier [Member]
Dec. 31, 2012
Servier [Member]
Dec. 31, 2011
Servier [Member]
Dec. 31, 2013
Servier [Member]
Second Right to Develop Collaboration [Member]
Dec. 31, 2012
Servier [Member]
Second Right to Develop Collaboration [Member]
Dec. 31, 2013
Gilead [Member]
Molecule
Dec. 31, 2013
Gilead [Member]
Minimum [Member]
Dec. 31, 2013
Gilead [Member]
Maximum [Member]
Dec. 31, 2013
Gilead [Member]
Expired Option Agreement [Member]
Molecule
Dec. 31, 2013
Gilead [Member]
License Agreement Terms [Member]
Molecule
Dec. 31, 2013
Gilead [Member]
Option Agreement [Member]
Program
Dec. 31, 2013
Boehringer [Member]
Payments
Molecule
Dec. 31, 2012
Boehringer [Member]
Dec. 31, 2011
Boehringer [Member]
Jan. 31, 2011
Boehringer [Member]
Series D-2 Convertible Preferred Stock [Member]
Oct. 31, 2010
Pfizer [Member]
Molecule
Dec. 31, 2013
Pfizer [Member]
Program
Dec. 31, 2012
Pfizer [Member]
Dec. 31, 2011
Pfizer [Member]
Dec. 31, 2013
Green Cross [Member]
Dec. 31, 2012
Green Cross [Member]
Dec. 31, 2011
Green Cross [Member]
Oct. 28, 2010
Eli Lilly [Member]
May 31, 2010
Eli Lilly [Member]
May 31, 2008
Eli Lilly [Member]
Dec. 31, 2013
Eli Lilly [Member]
Dec. 31, 2012
Eli Lilly [Member]
Dec. 31, 2011
Eli Lilly [Member]
License And Collaboration Agreements [Line Items]                                                                
Collaboration agreement date         November 2011     September 2012   January 2013           October 2010       October 2010       June 2010           October 2007    
Non-refundable upfront payment         $ 20,000,000     $ 20,000,000   $ 7,500,000           $ 15,000,000       $ 5,000,000 $ 5,000,000     $ 1,000,000           $ 41,000,000    
Additional license grant fees       15,000,000 30,000,000     65,000,000   7,500,000                                            
Clinical milestone payments       5,000,000 47,000,000     98,000,000               41,000,000         17,000,000     4,500,000                
Regulatory milestone payments         140,000,000     300,000,000               89,000,000                                
Sales milestone payments         208,000,000     630,000,000               83,000,000         195,000,000                      
Expected period of development         27 months     29 months   21 months                                            
Recognized revenue under agreement         21,300,000 9,100,000 900,000 8,600,000 2,000,000 8,000,000           14,400,000 11,700,000 8,900,000     3,500,000 5,500,000 5,200,000 100,000 100,000 100,000       800,000 31,200,000 30,900,000
Milestone payment         10,000,000                     5,000,000 2,000,000         500,000           5,000,000 50,000,000      
Deferred revenue         900,000 10,000,000   9,400,000 18,000,000             12,800,000 14,000,000             650,000 750,000              
Deferred revenue included in current liabilities 20,267,323   24,123,176     9,100,000   8,600,000 8,600,000 3,600,000           7,000,000 5,000,000       7,291 1,300,000   100,000 100,000              
Deferred revenue included in long-term liabilities 7,135,687   19,956,343     900,000   800,000 9,400,000             5,800,000 9,000,000             550,000 650,000              
Clinical milestone payments under agreement               5,000,000                                                
Review period       30 days                                                        
Commercialization of molecules                   4     1 1 2 10       2                        
Clinical milestone payments under agreement                     20,000,000 25,000,000                                        
Additional clinical, regulatory and sales milestone payments                     240,000,000 250,000,000                                        
Number of annual maintenance payments received                               3                                
Received including upfront, annual maintenance and milestone payment                               48,800,000                                
Preferred Stock purchased $ 83,622,358 $ 12,014,815                                 $ 10,000,000                          
Research obligation completion date                               2015-09         2014-01                      
Period of agreement                                       3 years                        
DART program                                         1                      
Term of the agreement                                               2020-06                
Review of clinical data                                                     1 year